What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

We delve into all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Wall Street Journal reporter John Carreyrou calls in to talk “Bad Blood,” his forthcoming book about how Theranos rose to a $9 billion valuation and then became a cautionary tale for tech and turtlenecks alike. Then we talk about the courtroom drama that awaits Valeant Pharmaceuticals (or whatever it’s going to be called) and explore how biotech’s latest boom cycle creates risk for mom-and-pop investors. Also there’s a lightening round, which, in retrospect, was perhaps ill-advised.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy